Draig Therapeutics

Draig Therapeutics is a clinical-stage biopharmaceutical company developing transformative, best-in-class therapies for major neuropsychiatric disorders, including Major Depressive Disorder. A Cardiff University spinout co-founded with SV Health Investors, Draig ("dragon" in Welsh) leverages its founders' expertise in modulating the core glutamate/GABA pathways that underlie synaptic excitation and inhibition imbalance in the brain. Its pipeline is led by DT-101, a next-generation AMPA receptor positive allosteric modulator (PAM) advancing toward Phase 2 in MDD, alongside DT-201 and DT-301, subtype-selective GABAA receptor modulators. The company launched from stealth in June 2025 with a $140 million (£107 million) oversubscribed Series A led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital, SV Health Investors, and ICG. Added to the API Evangelist network as a portfolio company of Canaan Partners.

Draig Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Therapeutics, and Neuroscience.

Draig Therapeutics’ developer surface includes support and 5 more developer resources.

🌐 Visit website 📡 Source on GitHub

9.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyPharmaceuticalsTherapeuticsNeuroscienceNeuropsychiatryDrug DiscoveryClinical StageCNS

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 9.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.9 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/draig-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 3

The organization behind the API

Website

Website

About

About

LinkedIn

Source (apis.yml)

aid: draig-therapeutics
name: Draig Therapeutics
description: Draig Therapeutics is a clinical-stage biopharmaceutical company developing transformative, best-in-class therapies
  for major neuropsychiatric disorders, including Major Depressive Disorder. A Cardiff University spinout co-founded with
  SV Health Investors, Draig ("dragon" in Welsh) leverages its founders' expertise in modulating the core glutamate/GABA pathways
  that underlie synaptic excitation and inhibition imbalance in the brain. Its pipeline is led by DT-101, a next-generation
  AMPA receptor positive allosteric modulator (PAM) advancing toward Phase 2 in MDD, alongside DT-201 and DT-301, subtype-selective
  GABAA receptor modulators. The company launched from stealth in June 2025 with a $140 million (£107 million) oversubscribed
  Series A led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital,
  SV Health Investors, and ICG. Added to the API Evangelist network as a portfolio company of Canaan Partners.
url: https://raw.githubusercontent.com/api-evangelist/draig-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-industry: Biotechnology
x-headquarters: Cardiff, Wales, United Kingdom
x-tier: profiled
x-tier-reason: portfolio-lead
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
image: https://draigtherapeutics.com/wp-content/uploads/2026/05/cropped-Draig_favicon-192x192.png
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Therapeutics
- Neuroscience
- Neuropsychiatry
- Drug Discovery
- Clinical Stage
- CNS
apis: []
common:
- type: DomainSecurity
  url: security/draig-therapeutics-domain-security.yml
- type: Website
  url: https://draigtherapeutics.com/
- type: About
  url: https://draigtherapeutics.com/our-approach/
- type: Support
  url: https://draigtherapeutics.com/contact/
- type: PrivacyPolicy
  url: https://draigtherapeutics.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/draigtherapeutics/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence